Lead investigator, SURPASS-CVOT trial
Appears in 1 story
SURPASS-CVOT led to the FDA's August 2026 approval of Mounjaro for cardiovascular risk reduction
The FDA approved tirzepatide (Mounjaro) on August 28 to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes at high risk. The decision rests on SURPASS-CVOT, a 13,000-patient trial that found tirzepatide matched an older GLP-1 medicine, dulaglutide (Trulicity), on major heart events, with an estimated 8% lower rate.
Updated Aug 29
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
